Seach Medical Group Ltd.
TTASE:SEMG258.70
ILA
-11.70
(-4.33%)
ISIN
IL0002490113
Return %
Stock
S&P 500
1Y
-8.07
14.20
3Y
82.44
81.12
5Y
-92.99
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Yogev Sarid
- Full Time Employees
- 160
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 23 Pami Aviv Giv'at Hen HM Israel 4390500
- IPO Date
- May 21, 1990
- Website
- seach.co.il
- Similar Companies
- Business
- Seach Medical Group Ltd (TASE: SEMG), formerly Beyond Time Holdings Ltd, manufactures and sells medicinal cannabis products worldwide. The company offers pure medical cannabis inflorescence; oil compounds featuring varying concentrations of cannabinoids including THC and CBD under the Nitzan brand name; power powder; moodpicks; and recently launched medical oils such as M.MAC Oil and GO.B Oil, tailored to patient needs through precise cultivation and the entourage effect of cannabinoids, terpenes, and flavonoids. It engages in propagation, cultivation, processing, production, marketing, and distribution of these products for medical use, targeting hospitals, clinical trials, and patients while participating in cannabis-related medical research and technology development. Seach Medical Group maintains certifications including EU-GMP capability through partners, ISO 9001 since 2016, and GACP in line with WHO guidelines for its cultivation facility. In a major strategic development, Seach Medical Group completed a reverse merger into publicly traded Beyond Time in 2024 for approximately $60 million, advised by Value Base M&A, transitioning to its current public listing and structure. The company, founded in 2002 by the Sarid family—third-generation agriculturalists—and headquartered at 23 Pami Aviv in Ramat Gan, Israel (also referenced as Giv'at Hen), operates primarily in the pharmaceuticals and biotech sector with a focus on specialty drug manufacturing. It employs 158 people under CEO Yogev Sarid and serves global markets with an emphasis on Israel as a pioneer in medical cannabis innovation since 2008.